Photo of Tom Powles taken from bartscancer.london
May 27, 2024, 05:34
Tom Powles: The ASCO 24 highlight In My Opinion
Tom Powles, Director of Barts Cancer Center, shared on X:
“The ASCO 24 highlight IMO. Currently 3 peri-operative IO approaches: adjuvant, neoadjuvant or both. NADINE tests neoadjuvant vs adjuvant. If +ve and neoadjuvant IO >adjuvant then shorter stronger peri-operative IO maybe better than longer adjuvant/combined approaches(+/- ctDNA)”
Source: Tom Powles/X